(UroToday.com) The 2024 American Urological Association (AUA) Annual Meeting held in San Antonio, TX was host to the International Prostate Forum. Dr. Jeremie Calais presented key updates in ...

WCET 2022: Assessing the Clinical Force Threshold for the Safe Deployment of a Ureteral Access Sheath Using a Ureteral Access Sheath Force Sensor. WCET 2022: Assessing the Impact Of Irrigation ...

ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304) ESMO 2024: HARMONY: A Phase II Study of ...

ASTRO 2021: 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation Therapy in Localized Prostate Cancer ASTRO 2021: Impact of AR-V7 and Other ...

ASCO GU 2022: First-Line Pembrolizumab with or Without Lenvatinib in Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Study. ASCO GU 2022: Bladder-Sparing ...

SCS AUA 2024: Pelvic Exenteration and Urologic Complications: A 90-Day Audit of the Practice at a Single Tertiary Level Medical Center SCS AUA 2024: Multiparametric MRI in the Evaluation of Small ...

Comparing Autologous and Mesh Slings for Stress Incontinence Efficacy and Safety - Ariana Smith ...

ESMO 2023: TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–Muscle-Invasive Bladder Cancer with Select FGFR Alterations: First Safety and Efficacy Results ESMO 2023: SunRISe-1: ...

Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin ...

ESMO 2024: NEOTAX: A Phase II Trial of Neoadjuvant Toripalimab plus Axitinib for Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus ESMO 2024: Systemic Treatment Options ESMO 2024: ...

Decipher mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth ...

This recent publication presents a novel machine learning-based predictive model for clinically significant prostate cancer, along with an online risk calculator. The model was developed using a ...